Prolonged Methamphetamine-Induced Psychosis: Difference With Schizophrenia
The main objective of the present study was to compare the distribution of underlying factors such as neurological soft signs, obstetric complications, and family history of psychiatric disorders between two groups of schizophrenic patients and patients with prolonged methamphetamine-induced psychosis. In a case-control study, 30 patients with prolonged methamphetamine-induced psychosis and 30 patients with schizophrenia were selected. Data were collected through a demographic questionnaire, the Buchanan and Heinrichs’ Neurological Evaluation Scale (NES), the Lewis-Murray’s Obstetric Complications Scale (LMOCS), and the Weissman’s Family History Screen (FHS). Mean scores of the neurological soft signs (±SD) in the two groups of schizophrenic patients and patients with prolonged methamphetamine-induced psychosis were 15.7±8.7 and 11.7±6.2, respectively (P=0.040), and a significant difference was observed in the sensory integration between the two groups (P=0.022). Obstetric complications revealed similar distributions in the two groups. Patients with prolonged methamphetamine-induced psychosis reported higher prevalence of alcohol and other substances use disorders (P=0.003 and P=0.001, respectively) in their close relatives; however, the distributions of other disorders were not statistically different between the two groups’ close relatives. Similarities and differences in certain aspects were observed between the two groups, suggesting susceptibility for psychosis in patients with prolonged methamphetamine-induced psychosis; yet we found diversities that distinguish the two disorders.
Sulaiman AH, Said MA, Habil MH, Rashid R, Siddiq A, Guan NC, et al. The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia. Comprehensive psychiatry. 2014;55:S89-S94. doi: http://dx.doi.org/10.1016/j.comppsych.2013.01.003.
World Drug Report 2012. United Nations Office on Drugs and Crime, 2012.
World Drug Report 2007. United Nations Office on Drugs and Crime, 2007.
UNODC. World Drug Report 2014: United Nations Office on Drugs and Crime; 2014.
Report of the International Narcotics Control Board for 2012. International Narcotics Control Board, 2012.
Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Murray RM. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2005;136(1):87-91. doi: https://doi.org/10.1002/ajmg.b.30187.
Bramness JG, Gundersen ØH, Guterstam J, Rognli EB, Konstenius M, Løberg E-M, et al. Amphetamine-induced psychosis-a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC psychiatry. 2012;12(1):221. doi: https://doi.org/10.1186/1471-244X-12-221.
Akiyama K, Saito A, Shimoda K. Chronic Methamphetamine Psychosis after Long‐Term Abstinence in Japanese Incarcerated Patients. The American Journal on Addictions. 2011;20(3):240-9. doi: https://doi.org/10.1111/j.1521-0391.2011.00124.x.
Hsieh JH, Stein DJ, Howells FM. The neurobiology of methamphetamine induced psychosis. Frontiers in human neuroscience. 2014;8. doi: https://doi.org/10.3389/fnhum.2014.00537.
Mikami T, Naruse N, Fukura Y, Ohkubo H, Ohkubo T, Matsuura M, et al. Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements. Psychiatry and clinical neurosciences. 2003;57(4):433-40.
Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-associated psychosis. Journal of Neuroimmune Pharmacology. 2012;7(1):113-39. doi: https://doi.org/10.1007/s11481-011-9288-1.
Chan RC, Xu T, Heinrichs RW, Yu Y, Wang Y. Neurological soft signs in schizophrenia: a meta-analysis. Schizophr Bull. 2009:sbp011.
Chan RC, Gottesman II. Neurological soft signs as candidate endophenotypes for schizophrenia: a shooting star or a Northern star? Neuroscience & Biobehavioral Reviews. 2008;32(5):957-71. doi: https://doi.org/10.1016/j.neubiorev.2008.01.005.
Chan RC, Xu T, Heinrichs RW, Yu Y, Gong Q-y. Neurological soft signs in non-psychotic first-degree relatives of patients with schizophrenia: a systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2010;34(6):889-96. doi: https://doi.org/10.1016/j.neubiorev.2009.11.012.
Sharifi V, Asadi S, Mohammadi M, Amini H, Kaviani H, Semnani Y, et al. Reliability and feasibility of the Persian version of the structured diagnostic interview for DSM-IV (SCID). Advances in cognitive science 2004;6(1-2):10-22.
Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry research. 1989;27(3):335-50.
Lewis SW, Murray RM. Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia. Journal of psychiatric research. 1987;21(4):413-21. doi: https://doi.org/10.1016/0022-3956(87)90088-4.
Weissman MM, Wickramaratne P, Adams P, Wolk S, Verdeli H, Olfson M. Brief screening for family psychiatric history: the family history screen. Archives of General Psychiatry. 2000;57(7):675-82.
McIntosh A, Holmes S, Gleeson S, Burns J, Hodges A, Byrne M, et al. Maternal recall bias, obstetric history and schizophrenia. The British Journal of Psychiatry. 2002;181(6):520-5.
Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. American Journal of Psychiatry. 2002;159(7):1080-92. doi: https://doi.org/10.1176/appi.ajp.159.7.1080.
Guerra A, Fearon P, Sham P, Jones P, Lewis S, Mata I, et al. The relationship between predisposing factors, premorbid function and symptom dimensions in psychosis: an integrated approach. European psychiatry. 2002;17(6):311-20. doi: https://doi.org/10.1016/S0924-9338(02)00685-5.
Tabatabaie MG, Zahra M, AbouAli V. Home birth and barriers to referring women with obstetric complications to hospitals: a mixed-methods study in Zahedan, southeastern Iran. Reproductive health. 2012;9(5). doi: https://doi.org/10.1186/1742-4755-9-5.
Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis: demographic characteristics, clinical features, and family history. Archives of General Psychiatry. 1982;39(2):141-7. doi: 10.1001/archpsyc.1982.04290020013003.
Pickens RW, Preston KL, Miles DR, Gupman AE, Johnson EO, Newlin DB, et al. Family history influence on drug abuse severity and treatment outcome. Drug and alcohol dependence. 2001;61(3):261-70.
Milne BJ, Caspi A, Harrington H, Poulton R, Rutter M, Moffitt TE. Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependence. Archives of general psychiatry. 2009;66(7):738-47.
Darijani N, Mirsepasi G, Sanati M, Novrouzian M. Soft neurological signs in paranoid and other subtypes of schizophrenia. Iranian Journal of Psychiatry and Clinical Psychology. 2000;6(22):6-15.
Bombin I, Arango C, Buchanan RW. Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophrenia Bulletin. 2005;31(4):962-77. doi: https://doi.org/10.1093/schbul/sbi028.
Sewell RA, Perry EB, Karper LP, Bell MD, Lysaker P, Goulet JL, et al. Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale. Schizophrenia research. 2010;124(1):1-12.
Smit I, Koen L, Niehaus D, Jordaan E, Botha U. Neurological soft signs as an endophenotype in an African schizophrenia population-a pilot study: original article. African journal of psychiatry. 2012;15(2):124-7. doi: http://dx.doi.org/10.4314/ajpsy.v15i2.17.
Tomiyama G. Chronic Schizophrenia‐Like States in Methamphetamine Psychosis. Psychiatry and Clinical Neurosciences. 1990;44(3):531-9. doi: https://doi.org/10.1111/j.1440-1819.1990.tb01626.x.
Jacobs E, Fujii D, Schiffman J, Bello I. An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia. Cognitive and Behavioral Neurology. 2008;21(2):98-103. doi: 10.1097/WNN.0b013e31816bdf90.
Cadet JL, Jayanthi S, Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotoxicity research. 2005;8(3-4):199-206.
Rodkong A, Intachai N, Saekho S, Sailasuta N, Aramrattana A, Uttawichai K, et al. P-54CORTICAL THINNING IN THAI METHAMPHETAMINE USERS: AN MRI STUDY. Alcohol and Alcoholism. 2014;49(suppl 1):i63-i4.
Eisch AJ, Marshall JF. Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse. 1998;30(4):433-45.
Ujike H, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, et al. Nine-or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. The pharmacogenomics journal. 2003;3(4):242-7. doi: 10.1038/sj.tpj.6500189.
Fan JB, Sklar P. Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Molecular psychiatry. 2005;10(10):928-38. doi: 10.1038/sj.mp.4001690.
Kishimoto M, Ujike H, Motohashi Y, Tanaka Y, Okahisa Y, Kotaka T, et al. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biological psychiatry. 2008;63(2):191-6.
Williams NM, O'Donovan MC, Owen MJ. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophrenia Bulletin. 2005;31(4):800-5. doi: https://doi.org/10.1093/schbul/sbi061.
Badner J, Gershon E. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Molecular psychiatry. 2002;7(4):405-11.
Kotaka T, Ujike H, Okahisa Y, Takaki M, Nakata K, Kodama M, et al. G72 gene is associated with susceptibility to methamphetamine psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009;33(6):1046-9. doi: https://doi.org/10.1016/j.pnpbp.2009.05.017.
Okochi T, Kishi T, Ikeda M, Kitajima T, Kinoshita Y, Kawashima K, et al. Genetic association analysis of NRG1 with methamphetamine-induced psychosis in a Japanese population. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009;33(5):903-5. doi: https://doi.org/10.1016/j.pnpbp.2009.04.016.
Ujike H, Sakai A, Nakata K, Tanaka Y, Kodaka T, Okahisa Y, et al. Association Study of the Dihydropyrimidinase‐Related Protein 2 Gene and Methamphetamine Psychosis. Annals of the New York Academy of Sciences. 2006;1074(1):90-6. doi: https://doi.org/10.1196/annals.1369.008
Gupta S, Andreasen NC, Arndt S, Flaum M, Schultz SK, Hubbard WC, et al. Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects. American Journal of Psychiatry. 1995;152(2):191-6.